Generic melphalan available in US

Print Friendly, PDF & Email


Fresenius Kabi’s Melphalan
Hydrochloride for Injection
Photo from Business Wire
Fresenius Kabi’s Melphalan Hydrochloride for Injection, a generic version of Alkeran®, is now available in the US. Melphalan Hydrochloride for Injection is available as a 2-vial kit containing 1 single-dose vial of melphalan hydrochloride equivalent to 50 mg of melphalan and 1 vial of... [Read Article]
Print Friendly, PDF & Email

Group identifies novel genes involved in MM development

Print Friendly, PDF & Email


Micrograph showing MM
Researchers have identified novel genes involved in the development of multiple myeloma (MM), according to a paper published in Leukemia. The team’s analyses revealed regions of coding and non-coding DNA that appear to drive MM development. The researchers analyzed whole-exome sequencing data from 804 MM patients and whole-genome sequencing data from... [Read Article]
Print Friendly, PDF & Email

Generic antiemetic now available in US

Print Friendly, PDF & Email


Fresenius Kabi’s Palonosetron
Hydrochloride Injection
Photo from Business Wire
Palonosetron Hydrochloride Injection, a generic alternative to Aloxi®, is now available in the US. Fresenius Kabi’s Palonosetron Hydrochloride Injection is a 5-HT3 serotonin receptor that is approved for the prevention of nausea and vomiting in certain adults. Palonosetron Hydrochloride Injection is available in a single-dose... [Read Article]
Print Friendly, PDF & Email

Selinexor receives fast track designation for MM

Print Friendly, PDF & Email


Micrograph showing
multiple myeloma
The US Food and Drug Administration (FDA) has granted fast track designation to selinexor for the treatment of patients with penta-refractory multiple myeloma (MM). The patients must have received at least 3 prior lines of therapy that included an alkylating agent, a glucocorticoid, bortezomib, carfilzomib, lenalidomide, pomalidomide, and daratumumab. In... [Read Article]
Print Friendly, PDF & Email

Screening may reduce prevalence of MM

Print Friendly, PDF & Email


Bone marrow aspirate
showing multiple myeloma
Targeted screening could potentially reduce the prevalence of multiple myeloma (MM), according to research published in JCO Clinical Cancer Informatics. Researchers found that screening for monoclonal gammopathy of undetermined significance (MGUS) might reduce the risk of MM in individuals with a high lifetime risk of MGUS, which includes... [Read Article]
Print Friendly, PDF & Email

EC expands indication for denosumab to MM

Print Friendly, PDF & Email


Vials of drug
Photo by Bill Branson
The European Commission (EC) has approved an expanded indication for denosumab (Xgeva). The drug is now approved for the prevention of skeletal-related events (SREs) in adults with advanced malignancies involving bone, which includes patients with multiple myeloma (MM). Approval from the EC provides a centralized marketing authorization with... [Read Article]
Print Friendly, PDF & Email

CHMP rejects plitidepsin again

Print Friendly, PDF & Email


Plitidepsin was discovered
in this marine macroorganism,
Aplidium albicans, but is
now synthesized.
Photo from PharmaMar
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended refusal of marketing authorization for plitidepsin (Aplidin). PharmaMar is seeking approval for plitidepsin to treat adults with multiple myeloma (MM) who have received at... [Read Article]
Print Friendly, PDF & Email

GPS plus lenalidomide may prolong PFS after ASCT

Print Friendly, PDF & Email


Guenther Koehne, MD, PhD
Photo courtesy of Baptist
Health South Florida
Post-transplant maintenance with galinpepimut-S (GPS) and lenalidomide may prolong progression-free survival (PFS) in patients with high-risk multiple myeloma (MM), according to new research. In a phase 2 trial, MM patients who received GPS and lenalidomide after autologous stem cell transplant (ASCT) had a... [Read Article]
Print Friendly, PDF & Email

Researchers question validity of NCCN guidelines

Print Friendly, PDF & Email


Cancer patient receiving chemotherapy
Photo by Rhoda Baer
New research suggests guidelines from the National Comprehensive Cancer Network (NCCN) may sometimes be supported by low-quality evidence or no evidence at all. Researchers compared NCCN recommendations for cancer drugs to US cancer drug approvals over a 5-year period. Thirty-nine percent of NCCN’s treatment recommendations... [Read Article]
Print Friendly, PDF & Email